The careful evaluation of drug use during pregnancy is crucial due to its implications for both the mother and the unborn child's health and well-being. However, Pakistan lacks essential information regarding medication usage during pregnancy, posing significant challenges in ensuring the safety of maternal-fetal health. This study, set to take place in Lahore's tertiary care facilities, aims to analyze prescriptions for possible drug-drug interactions (DDIs) and contraindications. It's imperative to tackle the public health risks linked with prescribing medications during pregnancy to improve patient safety. The study was conducted on pregnant women visiting tertiary care government hospitals in Lahore. The data was collected through consecutive sampling from (15-08-2023 to 15-11-2023). A total of 109 prescriptions were collected. The data was analyzed using SPSS for statistical analysis. In a clinical trial involving patients aged between 26 and 30 years, 109 prescriptions revealed diverse levels of drug-drug interactions (DDIs), with 58 interactions documented. The majority of DDIs were classified as minor (21.1%) or moderate (15.6%), except for a single prescription containing severe DDIs. Benefits include comprehensive prescription evaluations and insights into potential hazards, while drawbacks may involve possible bias and challenges in FDA categorization. Overall, the study highlights the significance of assessing medications for pregnant women and enhancing prescription protocols.